Idoxifene: Report of a Phase I Study in Patients with Metastatic Breast Cancer

Cancer Research

Volumn 55, Issue 5, 1995, Pages 1070-1074

  Coombes, R Charles ^a   Haynes, Ben P ^b   Dowsett, Mitchell ^c   Quigley, Mary ^a   English, Jacqueline ^a   Judson, Ian R ^b   Griggs, Lesley J ^b   Potter, Gerry A ^b   McCague, Ray ^b   Jarman, Michael ^b  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; IDOXIFENE; TAMOXIFEN;

ADVANCED CANCER; ANOREXIA; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FOLLITROPIN BLOOD LEVEL; HUMAN; LETHARGY; LUTEINIZING HORMONE BLOOD LEVEL; METASTASIS; MUSCLE WEAKNESS; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; ENDOCRINE GLANDS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; POSTMENOPAUSE; TAMOXIFEN;

EID: 0028935148     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Nayfield, S. G., Karp, J. E., Ford, L. G., Dorr, F. A., and Kramer, B. S. Potential role of tamoxifen in prevention of breast cancer. J. Natl. Cancer Inst., 83: 1450–1459, 1991.
2. Scholl, S. M., Huff, K. K., and Lippman, M. E. Antiestrogenic effects of LY117018 in MCF-7 cells. Endocrinology, 113: 611, 1983.
3. Lerner, L. J. The first non-steroidal antiestrogen—MER 25. In: R. C. Sutherland and V. C. Jordan (eds.), Non-steroidal Antiestrogens, pp 1–16. Sidney, Australia: Sydney Academic Press, 1981.
4. Valavaara, R., Pyrhonen, S., Heikkinen, M., Rissanen, P., Blanco, G., Tholix, E., Nordman, E., Taskinen, P., Holsti, L., and Hajba, A., Toremifene, a new antiestrogenic compound for treatment of advanced breast cancer: Phase II study. Eur. J. Cancer Clin. Oncol., 24: 785–790, 1988.
5. Wakeling, A. E., Dukes, M., and Bowler, J. A potent specific pure anti-estrogen with clinical potential. Cancer Res., 51: 3867–3873, 1991.
6. Love, R. R., Mazess, R. B., Barden, H. S., Epstein, S., Newcomb, P. A., Jordan, V. C., Carbone, P. P., and DeMets, D. L. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N. Engl. J. Med., 326: 852–856, 1992.
7. McCague, R., Leclerq, G., Legros, N., Goodman, J., Blackburn, G. M., Jarman, M., and Foster, A. B. Derivatives of tamoxifen: dependence of antiestrogenicity on the 4-substituent. J. Med. Chem., 32: 2527–2533, 1989.
8. Chander, S. K., McCague, R., Luqmani, Y., Newton, C., Dowsett, M., Jarman, M., and Coombes, R. C. Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer. Cancer Res., 51: 5851–5858, 1991.
9. McCague, R., Parr, I. B., and Haynes, B. P. Metabolism of the 4-iodo derivative of tamoxifen by isolated rat hepatocytes. Biochem. Pharmacol., 40: 2277–2283, 1990.
10. Osborne, C. K., Wiebe, V. J., and McGuire, W. L. Tamoxifen and the isomers of 4-hydroxy tamoxifen in tamoxifen-resistant tumours from breast cancer patients. J. Clin. Oncol., 10: 304–310, 1992.
11. Wolf, D. M., Langan-Fahey, M., Parker, C. J., McCague, R., and Jordan, V. C. Investigation of mechanism of tamoxifen-stimulated breast rumour growth with nonisomerizable analogues of tamoxifen and metabolites. J. Natl. Cancer. Inst., 85: 806–812, 1993.
12. Osborne, C. K., Jarman, M., McCague, R., Coronado, E. B., Hilsenbeck, S. G., and Wakeling, A. E. The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumour growth. Cancer Chemother. Pharmacol., 34: 89–95, 1994.
13. Rowlands, M. G., Parr, I. B., McCague, R., Jarman, M., and Goddard, P. M. Variation of the inhibition of calmodulin dependent cyclic AMP phosphodiesterase amongst analogues of tamoxifen: correlations with cytotoxicity. Biochem. Pharmacol., 40: 283–289, 1990.
14. Gulino, A., Barrera, G., Vacca, A., Farina, A., Ferretti, C., Screpanti, I., Diazani, M. V., and Frati, L. Calmodulin antagonism and growth inhibitory activity of triphenylethylene antiestrogens in MCF-7 human breast cancer cells. Cancer Res., 46: 6274–6278, 1986.
15. Sutherland, R. L., Watts, C. K. W., Hall, R. E., and Ruenitz, P. C. Mechanism of growth inhibition by non-steroidal antioestrogens in human breast cancer cells. J. Steroid Biochem. Mol. Biol., 27: 891–897, 1987.
16. Haynes, B. P., Parr, I. B., Griggs, L. J., and Jarman, M. Metabolism and pharmacokinetics of pyrrolidino-4-iodotamoxifen in the rat. Breast Cancer Res. Treat., 19: 174, 1991.
17. Willis, K. J., London, D. R., Ward, H. W. C., Butt, W. R., Lynch, S. S., and Rudd, B. T. Recurrent breast cancer treated with the antioestrogen tamoxifen: correlation between hormonal changes and clinical course. Br. Med. J., 1: 425–429, 1977.
18. Sakai, F., Cheix, F., Clavel, M., et al. Increases in steroid binding globulins induced by tamoxifen in patients with carcinoma of the breast. J. Endocrinol., 76: 219–227, 1978.
19. Hay ward, J. L., Carbone, P. P., Heuson, J-C. Kumaoka, S., Segaloff, A., and Rubens, R. D. Assessment of response to therapy in advanced breast cancer. Cancer (Phila.), 39: 1289–1294, 1977.
20. Dowsett, M., Goss, P., Powles, T. J., Hutchinson, G., Brodie, A. M. H., Jeffcoate, S. L., and Coombes, R. C. Use of the aromatase inhibitors 4-hydroxyandrostenedione in postmenopausal breast cancer: optimisation of therapeutic dose and route. Cancer Res., 47: 1957–1961, 1987.
21. Ferguson, K., Hayes, M., and Jeffcoate, S. L. Standardized multicentre procedure for plasma gonadotrophs radioimmunoassay. Ann. Biochem., 19: 358–367, 1982.
22. Dowsett, M., Attree, S., Virdee, S., and Jeffcoate, S. L. Oestrogen-related changes in sex hormone binding globulin levels during normal and gonadotrophin-stimulated menstrual cycles. Clin. Endocrinol., 23: 303–312, 1985.
23. Lien, E. A., Solheim, E., Lea, O. A., Lundgren, S., Kvinnsland, S., and Ueland, P. M. Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res., 49: 2175–2183, 1989.
24. De Vos, D., Slee, P. H. T. J., Stevenson, D., and Briggs, L. J. Serum elimination half-life of tamoxifen and its metabolites, in patients with advanced breast cancer. Cancer Chemother. Pharmacol., 31: 76–78, 1992.
25. Fabian, C., Sternson, L., and Barnett, M. Clinical pharmacology of tamoxifen in patients with breast cancer: comparison of traditional and loading dose schedules. Cancer Treat Rep., 64: 765–773, 1980.
26. Lien, E. A., Anker, G., Lonning, P. E., Solheim, E., and Ueland, P. M. Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. Cancer Res., 50: 5851–5859, 1990.
27. Stevenson, D., Briggs, R. J., Chapman, D. J., and De Vos, D. Determination of tamoxifen and five metabolites in plasma. J. Pharm. Biomed. Anal., 6: 1065–1068, 1988.
28. Johnston, S. R. D., Haynes, B. P., Sacks, N. P. M., MacKinna, J. A., Griggs, L. J., Jarman, M., Baum, M., Smith, I. E., and Dowsett, M. Effect of oestrogen receptor status and time on th intra-tumoral accumulation of tamoxifen and N-desmethylta-moxifen following short-term therapy in human primary breast cancer. Breast Cancer Res. Treat., 18: 241–250, 1993.
29. Jordan, V. C. Metabolites of tamoxifen in animals and man: identification, pharmacology and significance. Breast Cancer Res. Treat., 2: 123–138, 1982.
30. Soininen, K., Kleimola, T., Elomaa, I., Salmo, M., and Rissanen, P. The steady-state pharmacokinetics of tamoxifen and its metabolites in breast cancer patients. J. Int. Med. Res., 14: 162–165, 1986.
31. Reid, A. D., Horobin, J. M., Newman, E. L., and Preece, P. E. Tamoxifen metabolism is altered by simultaneous administration of medroxyprogesterone acetate in breast cancer patients. Breast Cancer Res. Treat., 22: 153–156, 1992.
32. Langan-Fahey, S. M., Tormey, D. C., and Jordan, V. C. Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer. Eur. J. Cancer., 26: 883–888, 1990.
33. Johnston, S. R. D., Haynes, B. P., Smith, I. E., Jarman, M., Sacks, N. P. M., Ebbs, S. R., and Dowsett, M. Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoural drug concentration. Lancet, 342: 1521–1522, 1993.
34. Robinson, S. P., Langan-Fahey, S. M., Johnson, D. A., and Jordan, V. C., Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab. Dispos., 19: 36–43, 1991.